On March 20, 2014, ARCA Biopharma (NASDAQ:ABIO) filed its Form 10-K annual report for the period ending December 31, 2013, providing investors an update on the financial position and business prospects for the company. A quick look at the financials and we see that ARCA reported no revenues in 2013, as expected, and a net loss of $9.0 million, or $1.04 per share. Net cash usage from operating and investing activities in 2013 totaled $5.3 million, with $1.9 million coming in the fourth quarter 2013. ARCA funded operations in 2013 through $19.2 million in financing activities, driven primarily by a $20 million public offering that took place in June 2013.
ARCA exited 2013 with $16.8 million in cash
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|